FEATURED EDITORIAL
The latest generation of LNP technologies holds the promise of delivering therapies to precise cells and tissues outside the liver, while mRNA technology allows transient protein expression to be maintained.
- From Receptor Signaling to Therapeutic Design: Rethinking Antibody Discovery
- Are NAMs Validation Centers Really Needed To Drive Greater NAMs Adoption? Scientists Are Wondering
- Years Before Clinical Trials: The Decisions That Shape The Future Of Academic Cancer Discoveries
- Targeting MSH3 To Slow Huntington's Disease Progression
- The 2026 Pharma R&D AI Sourcing Map: Partnerships, Concentration, Inflection
- How Peptides Are Expanding The Possibilities Of Drug Discovery
- Botanical QT Risk Starts In The Extract
FEATURED APPLICATION CONTENT
-
ADC programs move fastest when payload-linker strategy, route design, conjugation, and drug product are planned together, with timelines and scale-up capacity shaping choices from the earliest development stages.
-
Uncover how EPR spectroscopy fills the conformational gap by capturing dynamic protein motions, refining Cryo-EM models, and revealing hidden structural ensembles for drug discovery.
-
Growing demand for cell and gene therapies is increasing pressure on cytokine production. Explore interleukin manufacturing, quality, consistency, safety, scalability, and supply reliability.
-
Accelerate recombinant protein development from sequence to scale while maintaining stable expression, manufacturing efficiency, and critical quality attributes.
-
See how expression hosts affect recombinant EPO glycosylation, bioactivity, and consistency, with reproducible N-glycan profiles and absence of α1,3-linked fucosylation.
-
Explore how D. mel-derived human prolactin (hPRL) compares with hPRL expressed in E. coli and HEK293 cells through detailed physico-chemical and biological characterization.
-
A material-sparing strategy integrating formulation mapping, lab-scale spray drying, and compact screening can accelerate risk identification and inform first-round tablet formulation decisions for poorly soluble APIs.
-
A CDMO-authored framework for navigating dry powder inhaler development, covering target product profile definition, API characterization, particle engineering technology selection, and encapsulation considerations.
-
SDD scale-up introduces scale-dependent risks that threaten bioavailability, stability, and manufacturability. This white paper details a model-based framework for managing those risks from early feasibility through commercial production.
-
Despite more than 125 ADCs entering clinical trials, only four have reached approval. This review examines why enzymatic conjugation strategies may change that trajectory.
-
A chemoenzymatic two-stage protocol enables DAR2 ADCs from native, non-engineered mAbs via glycan remodeling at Asn-297 and copper-free click chemistry, with in vivo efficacy outperforming a comparable marketed ADC.
-
Antibody-oligonucleotide conjugates introduce conjugation and purification challenges that standard ADC process development wasn't designed to solve. This white paper details practical approaches for each.
- Are NAMs Validation Centers Really Needed To Drive Greater NAMs Adoption? Scientists Are Wondering
- Built To Avoid Risk: How Industry Norms Stall Drug Discovery
- Can CoRegen's Treg Platform Dismantle Solid Tumors' Immune Shield?
- Discovery & Development US 2026 - Key Notes From San Diego
- Inside Discovery On Target 2026: New Modalities, AI, And A Higher Funding Bar
EDITORIAL COLLECTIONS
Examine the scientific questions and emerging approaches shaping drug discovery today. Our Editorial Collections gather relevant research, examples, and perspectives in one convenient resource.
FEATURED NEWS HEADLINES
- FDA's Early-Phase Solid Tumor Guidance Narrows The First-In-Human Objective
- Who Gets Bench Time When Anyone Can Design A Protein?
- DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery And Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
- Ten63 Therapeutics Launches BEYOND-Alpha, With Chugai Pharmaceutical As First Participant
- Genomics Ltd. Announces Extension Of Strategic Drug Discovery Collaboration With Vertex Pharmaceuticals
- A Validated Target Is No Longer A De-Risked Program
- GATC Health And Hesperos Partner To Build FDA-Aligned NAMs Workflow That Aims To Cut Time And Cost Of Preclinical Testing
- Karyopharm Announces FDA Acceptance Of Supplemental New Drug Application For XPOVIO® (Selinexor) Plus Ruxolitinib For The Treatment Of Patients With Myelofibrosis
- Don't Discard Your Animal Data Yet
- RushDATA Delivers Wet-Lab Validation For AI-Designed Antibodies From Molence Bio's Mol-1
ARCHIVED NEWSLETTER
- 11.19.26 -- What If The Body Could Make Its Own Medicine?
- 11.19.26 -- Advance Discovery With Analytical Characterization Solutions
- 11.18.26 -- Is It Time To Rethink Your Protein Expression Strategy?
- 11.12.26 -- Imaging & Translational Models: Solutions For Smarter Discovery
- 11.11.26 -- The Early ADC Decisions That Reach Commercial Scale
